FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

X	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
---	--

1. Name and Address of Reporting Person [*] Rodman David Malcom			2. Issuer Name and Ticker or Trading Symbol <u>Mineralys Therapeutics, Inc.</u> [MLYS]		tionship of Reporting Pers all applicable) Director	on(s) to Issuer 10% Owner			
(Last) 150 N. RADNO			3. Date of Earliest Transaction (Month/Day/Year) 05/09/2024	x	Officer (give title below) Chief Medica	Other (specify below)			
SUITE F200 (Street) RADNOR PA 19087		19087 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi X	idual or Joint/Group Filing Form filed by One Rep Form filed by More than	,			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. Transac Code (Ir 8)		Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
				v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	05/09/2024		M ⁽¹⁾		100	A	\$1.08	67,097	D	
Common Stock	05/09/2024		S ⁽¹⁾		100	D	\$15	66,997	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		5. Num Derivat Securit Acquir or Disp of (D) (4 and 5	tive ties ed (A) oosed Instr. 3,	Expiration Date (Month/Day/Year)		Securities Underlying		8. Price of Derivative Security (Instr. 5)	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$1.08 ⁽²⁾	05/09/2024		M ⁽¹⁾			100	(3)	07/11/2031	Common Stock	100	\$0	203,054	D	

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

2. Due to a rounding error, the exercise price for this stock option was originally reported as \$1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

3. The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

Remarks:

s/ Adam Levy, Attorney-in-fact 05/10/202	0/2024
--	--------

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.